Saturday, March 25, 2023
News
NEWS HOME
»
PRN INDIA
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
  SocialTwist Tell-a-Friend  
   

  • ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.
  • ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.
  • ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need.

FLORENCE, Italy and NEW YORK, Jan. 30, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has approved  ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, headquartered in New York and focused on bringing transformational oncology treatments for cancer patients, will commercialize ORSERDU in the U.S.

Menarini Group Logo

"The FDA approval of ORSERDU marks the first ever therapy for ER+, HER2- advanced or metastatic breast cancer patients with ESR1 mutations and we are very proud to offer a targeted therapy addressing this huge unmet need," commented Elcin Barker Ergun, Chief Executive Officer of the Menarini Group. "We are grateful to the patients, investigators and administrators who participated in the clinical trials that led to this remarkable innovation."

ORSERDU is approved under the FDA's Priority Review and Fast Track designation based on the results of the registrational Phase III trial EMERALD, that demonstrated statistically significant progression-free survival (PFS) with elacestrant vs SOC endocrine monotherapy (fulvestrant, letrozole, anastrozole, exemestane), meeting both primary endpoints in all patients and in those patients whose tumors harbor ESR1 mutations.

In the group of patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45% (PFS HR=0.55, 95% CI: 0.39, 0.77) vs SOC. A post-hoc analysis of the PFS results based on the duration of prior CDK4/6i inhibitors (CDK4/6i) usage was presented at San Antonio Breast Cancer Symposium (SABCS) in December 2022. The median PFS was 8.6 months on elacestrant vs 1.9 months for SOC, in those patients whose tumors harbored ESR1 mutations and had been treated with a CDK4/6i for at least 12 months.

Safety data is consistent with the other endocrine therapies. Most of the adverse events (AEs), including nausea and musculoskeletal pain were grade 1 and 2. No hematological safety signal was observed and none of the patients in either of the two treatment arms had sinus bradycardia.

"Advanced or metastatic ER+, HER2- breast cancer pre-treated with endocrine-based therapy remains an area of unmet medical need. The last endocrine therapy approved was about 20 years ago, and effective endocrine options for this patient population are needed," said Dr. Aditya Bardia, MD, MPH, Director of Breast Cancer Research at Mass General Cancer Center, Associate Professor at the Medicine Department at Harvard Medical School, and Principal Investigator for the EMERALD trial. "ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. The approval of elacestrant is welcomed as it offers a novel option for patients with ER+, HER2- metastatic breast cancer. This therapy targets the ESR1 mutations in metastatic breast cancer and provides patients with a convenient oral once-daily dose."

"Each year 300,000 Americans are diagnosed with breast cancer and metastatic breast cancer causes  the vast majority of  deaths from the disease: more than 43,000 annually. We urgently need new and better treatment options to extend and improve the lives of people with metastatic breast cancer," said Sonya Negley, Executive Director, Metavivor. "We are thrilled to see the approval of ORSERDU, a new oral endocrine therapy, for patients who have tumors that harbor ESR1 mutations, which are present in up to 40% of ER+, HER2- advanced or metastatic breast cancer. We advise patients to get tested for ESR1 mutations  at progression in their metastatic treatment, so that their healthcare team can identify the right treatment options for their disease."

ORSERDU  will soon be available in the United States.  Stemline is committed to helping patients access ORSERDU  and will be offering services to overcome access barriers.  Stemline ARC, a patient support program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identify potential financial assistance options. For more information, patients and healthcare professionals can call 1-833-4-STEMLINE (1-833-478-3654)

The Menarini Group obtained global licensing rights for elacestrant in July 2020 from Radius Health, Inc., who conducted the EMERALD study.   With this approval, Radius will receive milestone payments and royalties from commercial sales. The Menarini Group is now fully responsible for global registration, commercialization, and further development activities for elacestrant.

About EMERALD Phase 3 Study (NCT03778931)
The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+, HER2- advanced/metastatic breast cancer patients. The study enrolled 478 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator's choice of an approved hormonal agent. The primary endpoints of the study were progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations.

About ORSERDU (elacestrant)
The U.S. Food and Drug Administration (FDA) has approved  ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. The Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA).

Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies: ELEVATE (NCT05563220); ELECTRA (NCT05386108); ELONA (NCT05618613); ELCIN (NCT05596409). Elacestrant is also planned to be evaluated in early breast cancer disease.

Full prescribing information can be found at www.orserdu.com

Important Safety Information

Warning and Precautions

Dyslipidemia: Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively.   Monitor lipid profile prior to starting and periodically while taking ORSERDU.

Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman.   Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose.

Adverse Reactions

Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each).

The most common adverse reactions (>10%), including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%).

Drug interactions

Concomitant use with CYP3A4 Inducers and/or inhibitors:   Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU.

Use in specific populations

Lactation: Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose.

Hepatic Impairment: Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B).

The safety and effectiveness of ORSERDU in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at  1-877-332-7961 or FDA at  1-800-FDA-1088  or  www.fda.gov/medwatch.

Indication
ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

For more information, please see the full Prescribing Information for ORSERDU here

About The Menarini Group
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com.

About Stemline
Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes Elzonris ®, a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic cancer, in the United States and Europe, the only approved treatment for BPDCN in the US and EU to date. Stemline also commercializes Nexpovio ® in Europe, an XPO1 inhibitor for multiple myeloma originating from a licensing deal with Karyopharm. Stemline has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.

Logo - https://mma.prnewswire.com/media/1958938/MENARINI_GROUP_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/stemline-therapeutics-a-subsidiary-of-menarini-group-receives-us-fda-approval-for-orserdutm-elacestrant-as-the-first-and-only-treatment-specifically-indicated-for-patients-with-esr1-mutations-in-er-her2--advanced-or-metast-301733294.html

More News by PR Newswire India

Yili Group Wins 17 World Food Innovation Awards

IBC Demonstrates Highly Selective, High Yield (99+%) Direct Lithium Extraction from Brine at Salar de Maricunga, Chile using Direct Lithium to Product™ (DLP™) Process

James Dyson Award 2023 is Now Open for Entries; Indian Students Eligible for Prize Money of 5 lakh

LOUIS XIII COGNAC UNVEILS RARE CASK 42.1

GoingZero Offering FREE Shipping To Celebrate 100K Orders

HarperCollins presents The Bandit Queens by Parini Shroff

UKIBC brings together businesses, UN, UK government and partners on critical SDG matters in Delhi

THE NDC PARTNERSHIP SUPPORTS COUNTRIES TO LEVERAGE OPPORTUNITIES ACROSS THE WATER-CLIMATE NEXUS

Charting Towards a Multilingual and Inclusive Internet

CGTN: How China continues optimizing its COVID-19 response amid other outbreaks

Comviva wins Golden Peacock Innovation Award for the BlueMarble Digital Customer Experience solution

Hexaware CEO, R Srikrishna Recognized among the Most Promising Business Leaders of Asia at The Economic Times Asian Business Leaders Conclave, 2023

Maruti Suzuki Devils Circuit Completes its 50th Edition

aastey launches first loungewear collection - Airport Looks for all women

A23 Launches New Set of Brand Films; Highlights Product Offerings and Responsible Gaming

Amtex Systems partners with CYGNVS™ to provide Enhanced Cyber Resilience solutions in India

Former President Kovind releases Shoolini and AIU joint publication

Newgen Named as a Leader in Analyst Report on Content Platforms, Q1 2023

Unified Payments Interface (UPI) makes India a global leader in next-generation real-time payments infrastructure - FIS' 2023 Global Payments Report

AMITY UNIVERSITY MAHARASHTRA HOSTS ITS CONVOCATION CEREMONY AT MUMBAI CAMPUS

Prime Focus Technologies launches CLEAR® Localize at NAB 2023

Shanghai Electric Joins Forces with Global Industrial Partners to Promote Strategic Layout of Multi-energy Coupling and Complementary Mode

Resident Evil 4 releases today, March 24th - Free Demo is also available for download

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Otr Elkalam: The Largest International Competition for Quran Recitation and Adhan Is Back in Saudi Arabia

ViewSonic Releases a Brand-New Collection of Portable Pen Displays for the Creator Community

Bluehost Launches New Commerce Solutions for WordPress

Picarro and LESNI Partner to Deliver Comprehensive Ethylene Oxide Monitoring Solutions to Sterilization Facilities Worldwide

INX Announces First-Ever Blockchain-Powered Dividend Distribution

United Nations Development Programme Collaborates with Infosys Public Services to Implement Oracle Fusion Cloud Applications Suite

FII Institute Announces Featured Speakers for Global PRIORITY Summit in Miami

Tata AIA Life Insurance Launches NFO Offerings

GWM TANK500 HEV Launches in Thailand and Opens Global First Pre-sale

FP Markets launches cTrader to compliment its existing market-leading offering

Syncron Automated Dealer-to-Dealer Inventory Solution Named an OEM Off-Highway 2022 Top New Product Award Recipient

Global Heart Hub and the Global Coalition on Aging launch a Global Position Paper on Heart Valve Disease (HVD) and the Healthy Aging Agenda

Dombey Introduces the epic cryptocurrency mining apparatus

Zama Selected as Finalist for RSA Conference 2023 Innovation Sandbox Contest

Hyperscaling in turbulent times: A BCG - Times Bridge - TiE Delhi-NCR report

HGC and AMS-IX start new Internet Exchange in Manila

BTCEX Partners with W Economy TV to Invest in South Korea's Blockchain Technology through Memorandum of Understanding

TCL Announces 2023 Global Sponsorships Highlighting the Powerful Connection Between Technology and Sports

OMNICOM MEDIA GROUP RANKED #1 FOR 2022 INCREMENTAL BILLINGS GROWTH AMONG GLOBAL MEDIA MANAGEMENT GROUPS

Secureworks Reports 120% Growth in Annual Taegis Revenue to $188 Million in Connection with Fourth Quarter and Full Year Fiscal 2023 Results

WordUp, an AI-based English learning App, Introduces Fantasy Chat

Zendure Announces BOÉ Motorsports Sponsorship

Bitget Invests $30M in BitKeep Broadening Its Ce-DeFi Ecosystem

Group-IB's Fraud Protection most complete anti-fraud solution on market -- Frost & Sullivan

Mercedes-Benz & Other Prizes Found Their Owners in FBS Raffle

Thailand's Economy in Game-Changing Move With New Investment Strategy, BOI Article Says

Hexaware and Xceptor Partner to Offer Innovative Data Automation Solutions for Banking and Financial Services

PAPYRUS by Wemade is the world's first token gating messenger app

AFC Energy launches new advanced "Ammonia to Hydrogen" cracker technology

Singapore International Festival of Arts 2023 Explores the Spectrum of the Human Experience

Meishe Releases Web Editor Version 3.0, Integrates AIGC Digital Human Content Production

UST Named a 'Great Place to Work' and a 'Top Employer' for 2023 in the UK

Planned CapEx of INR 16,100+ crores from Indian Specialty Chemicals over the next 3 years: Windmill Capital

BTCEX and W Economy TV Launch Partnership Program to Foster Increased Collaboration

Pylontech's Marine Lithium-ion Battery System Receives JET Certificate in Japan

Nissan reveals prototype sedan for contemporary lifestyles

Zenarate Applauded by Frost & Sullivan for Reducing Costs and Improving Customer Experience in Contact Center to Deliver Value

Kotak811 Savings Account Experience Becomes Easier With V-KYC: Apply For The Video KYC From The Comfort of Home

ViewSonic Launches World's First Projectors Designed for Xbox

Accelex Introduces First Fully Automated Document Acquisition Solution for Private Markets

Digital Cooperation Organization welcomes Six New Observers

Leading US-Africa Trade and Investments Initiative, Prosper Africa Partners with Africa Fintech Summit as Gold Sponsor

Supermicro Expands GPU Solutions Portfolio with Deskside Liquid-Cooled AI Development Platform, Powered by NVIDIA

Leading CE & Telecoms Speakers Unite at Inaugural OpenSync Summit to Usher in New Era for Open-Source Cloud Services

New Software for SmartChem® Discrete Analyzer Improves User Experience

PSP Investments' updated Corporate Governance and Proxy Voting Principles reflect increased momentum to address climate change and execution of Climate Strategy

Yili obtains international water footprint verification both at the product and organizational levels

Amogy Secures $139 Million Series B-1 Round of Funding, Moving the Transportation Industry Closer to Clean Energy

Secureworks Reduces Cyber Risk and Bolsters Cyber Resiliency With Launch Of Security Posture Dashboard

454MW Astronergy TOPCon PV Modules Signed to Offer for Huge Brazilian Project

Bitget Invests US$30M In Multi-Chain Wallet BitKeep

QS World University Rankings by Subject 2023

Pinnacle Group Announces Gudi Padwa offers on Residential and Commercial Projects

STL replenishes 1.4 billion litres of water for ~40,000 lives in Maharashtra

DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM

The Spring Equinox Arrives with a Fresh Start of Warm Breeze: 133rd Canton Fair to Invite Global Buyers to Explore the Spring with High-Quality Products

ISKCON Bhiwandi wins the most committed NGO of the year award at CSR Summit'2023

Changing Trends in Campus Recruitment Explored at SPJIMR TPO Summit in Hyderabad

The Art of Living Social Projects: Paving the way towards making India water-rich

StoneX and ACX to Collaborate to Create U.S. Digital Carbon Marketplace

Ex-Amazon Leader, Sai Kotha, Joins XPDEL as the Senior Vice President

ALT DRX, World's First Digital Real Estate Exchange, raises $ 3.6 million

Xinhua Silk Road: SE China Fujian's Jinjiang plans multiple expos, sports events to boost high-quality development

Eka completes 23 new customer implementations, strengthens focus on customer success in 2022

TĂśV Rheinland achieves accreditation as CDP partner

Xinhua Silk Road: Chinese machinery equipment maker Zoomlion inks deals totaling RMB600 mln at CONEXPO-CON/AGG

SIMS METAL ACQUIRES NORTHEAST METAL TRADERS

CGTN: China-Russia ties deepened as Xi stresses 'new chapter' in his visit

BuildTech Asia 2023 to focus on Digitalisation, Smart Building & Construction and Sustainability

Casio to Release New EDIFICE Incorporating Design Features from the NISMO Ace Racing Car

Australia creating world-first 'weather service' for water quality

Supermicro Accelerates the Era of AI and the Metaverse with Top-of-the-Line Servers for AI Training, Deep Learning, HPC, and Generative AI, Featuring NVIDIA HGX and PCIe-Based H100 8-GPU Systems

Shutterstock Teams With NVIDIA to Build AI Foundation Models for Generative 3D Artist Tools

Locus Unveils 'ShipFlex' To Equip Businesses With Flexible & Intelligent Third-Party Delivery

CCTV+: Video Series on Classics Quoted by Xi to Be Aired on Russian Media

Global Fab Equipment Spending on Track for 2024 Recovery After 2023 Slowdown, SEMI Reports

Miral announces the much-anticipated SeaWorld® Yas Island, Abu Dhabi to open its doors on 23 May 2023

Ataccama ONE Now Available in the Microsoft Azure Marketplace

RESTORE: The Foundation for Reconstructive Surgery 15th Anniversary Fundraiser Dinner Gala

Shure Applauded by Frost & Sullivan for Providing Enhanced Experiences That Transform Workplaces into Collaboration Hubs Employees Want

DigiBoxx Makes Cloud Storage Affordable for Indian Individuals and Businesses

Former WHO officials highlight science-backed solution to reduce tobacco harm

Tech4Nature: Why Healthy Forests Mean Healthy People

CLEARBLUE MARKETS ANNOUNCES ROYAL BANK OF CANADA AS MINORITY INVESTOR AS PART OF SERIES A FINANCING

Snapmint wins the 'Best Mobile App Initiative of the Year' Award at 2nd Annual NBFC & Fintech Excellence Awards, 2023

SPJIMR Launches Innovative Accelerator Programme for Startups in Finance Industry

Family businesses see largest growth increase in 15 years: traits like values, employee communication, digital capabilities stand out in companies which outperformed peers: PwC Global Family Business Survey

Tsinghua University Launches 'International Joint Mission on Climate Change and Carbon Neutrality' to Demonstrate Environmental Commitment

PLASTIC THREATENS HUMAN AND PLANETARY HEALTH

CCTV+: The Global Youth Sharing Meeting on Liangzhu Culture

Delhi to Host International Conference on Blended Learning Ecosystem for Higher Education in Agriculture Today

KPMG announced winner of Central Banking's 'Risk Management Services Award'

SINGAPORE COCKTAIL FESTIVAL RETURNS WITH A 17-DAY SPIRITED CALENDAR FROM 5 TO 21 MAY 2023

Course5 Intelligence Integrates OpenAI's GPT Models with their Enterprise Analytics Platforms

Foundation for Neglected Disease Research (India) and DevsHealth (Barcelona) announce a collaboration to discover and develop affordable drugs for mosquito-borne infections using AI/ML technology

Xinhua Silk Road: Yubei District of China's Chongqing increases efforts to complete industrial chains and boost investment

Moving Solutions launches Home Improvement & Value-added services

HORIBA India extends its CSR support to Human Empowerment Foundation which supports Khelo India Stag Table Tennis Academy for strengthening Indian sports

Financing the transition: How to make the money flow for a net-zero economy

Developers of NFT Gaming Metaverse Raise 30M from Community and Players in World's Longest Token Sale

DICTADOR'S MIKA, THE WORLD'S FIRST AI CEO HUMANOID MADE A POWERFUL APPEARANCE AT THE SALZ21-HOME OF INNOVATION CONFERENCE

CGTN: Xi's Russia visit to launch 'new vision' for bilateral ties

Thailand BOI Approves 56.6 Billion Baht Investment Projects, Announces March Kick Off for "HQ Biz Portal" Service, Details Updated LTR Visa Criteria

Aramco and DHL Supply Chain announce new end-to-end Procurement and Logistics Hub joint venture

Waterfall Security Announces New WF-600 Unidirectional Security Gateway

Relativity Celebrates AI Innovation and Advancement at Legalweek 2023

Building Back: Helping Young People Go from Recovery to Discovery

Firmenich recognized as one of the 2023 World's Most Ethical Companies®

Al-Abdullah Group (Qatar) Invests $50 Million in Kabira Mobility, an Electric Vehicle Start-up

CGTN: President Xi's Russia visit to promote world peace, boost global development

Infinity Power Finalizes Acquisition of Lekela Power in Africa's Biggest Renewable Energy Deal

Zoomlion Wins $87.28 Million of Orders at CONEXPO-CON/AGG 2023

Wialon Telematics Platform Reaches 3.5 Million Connected Vehicles Worldwide

FDI World Dental Federation calls for global leaders to prioritise action against oral diseases at major UN meeting on health

INDIA'S TOP STUDENT VOLUNTEERS FELICITATED AT PRAMERICA EMERGING VISIONARIES AWARDS 2023

Gotion High-tech and Edison Power Co., Ltd. Reached a Strategic Cooperation

Leading the Trend of Pickup Trucks, a New GWM PICKUP Model debuts in the Middle East

Lendingkart Is Now Great Place To Work Certified

India Ratings Upgrades DCW to 'IND A'/Stable

Rummy Premier League 12 offering a whopping big prize pool of ₹75 crores is live on Junglee Rummy

Malaika Arora, Dia Mirza, Niharika NM, and many others to attend TechSparks Mumbai

PureSoftware showcases 5G Network Listening Module at Mobile World Congress 2023

Xinhua Silk Road: SEG Solar completes acquisition of 2GW PV module manufacturing facility in Houston, Texas

SEVERAL PATENTS GRANTED ACROSS THE US AND THE EU, STRENGHTENING THE INTEGRATEDXR® IP

CGTN:A look at China's democracy: What is the essence?

CGTN: China's vision of community with shared future for mankind builds global consensus

Educate Girls' Project Pragati aims to empower adolescent girls and young women with a second chance at education

INR 2.5 Cr funding won by Social Startups from IIITH's social incubator AIC-IIITH

133rd Canton Fair to be held onsite from April 15 to May 5 in 3 phrases

Dombbit- The Next Disruptive Technology in the Cryptocurrency Market

CliCli Showcases User Generated Content Editor and Platform at GDC 2023

Abracon Welcomes Cole Sikes as Vice President of Global Distribution and EMS

Get First Access to Pre-Token Markets with prePO

Quest Global Reinforces Commitment to Encourage India's Future Engineers, Concludes 11th Edition of Ingenium in Kochi

Maple announces 21% discount on iPhone 14 as their Gudi Padwa Offer

Healthium Medtech announced as the 'Official Healthcare Partner' by Boxing Federation of India for the IBA Women's World Boxing Championship 2023

AMARIS by Prerna Rajpal Offers Iconic Designs and Innovation in Fine Jewelry

VisionGATE is proud to announce All India Rank 1 for GATE Exams with their student, Jayadeep More

Akamai Mitigates Record DDoS Attack in Asia-Pacific (900 Gbps)

CONEXPO CON/AGG 2023: XCMG Machinery Unveils Its New US Brand Strategy

Basant Maheshwari Wealth Advisers Launch BM Nifty Top 20 smallcase

CATL presents liquid-cooling CTP energy storage solutions at World Smart Energy Week

THE 'BALTIC', A RARE 292-YEAR-OLD GUARNERI VIOLIN, SOLD FOR $9.44 MILLION AT TARISIO NEW YORK

Actor and director Patrick Duffy International Guest of Honour at the St. Patrick's Day Parade

ViewSonic Unveils Hybrid Learning Innovations with Stunning 105" 5K Interactive Display at BETT 2023

INX ANNOUNCES INTEGRATION WITH POLYGON

Via acquires Citymapper to expand its end-to-end TransitTech solution

SAFe® 6.0 and SAFe® Studio Platform: Changing the Way Enterprises Achieve Business Agility

Moldcell launches first-of-its-kind Digital Wallet - moldcell money, supported by Comviva

Altair Announces Altair RapidMiner: One Converged Platform for Data Analytics and Artificial Intelligence

Kohler India Embraces Equity at Pecha Kucha Event 2023

The Art of Living JalTara - a reliable and vigilant solution tackles the upsurging climate crisis in India

Intella X will be Showcasing Its Web3 Platform and Games at GDC with Polygon Labs

Cleartrip is your one-stop travel destination this summer; launches bus services in 90+ cities and the first edition of #NationOnVacation

Godrej Tyson Foods showcases its extensive portfolio of Yummiez and Real Good Chicken at AAHAR 2023

Expedia Recognizes RateGain as an Elite Connectivity Partner for 2023

Exploring the Innovative R&D Robotics Lab at Arya College Jaipur

ASIA'S 50 BEST RESTAURANTS UNVEILS THE 51-100 LIST FOR 2023

Chandigarh University becomes the Only Private University in India to win AIU'S Overall Trophy Two Times Consecutively

Delsey's 2022 full year results show 124% YoY net sales growth, EBITDA 6-fold increase compared to pre-pandemic levels

SEGi takes 'borderless learning' to new heights as MetaMentor goes live

LDRA Simplifies CAST-32A & A(M)C 20-193 Compliance With Complete Lifecycle Support

Hero Future Energies signs MoU with Andhra Pradesh Government to develop Renewable energy capacity

Sustainability Takes Center Stage at Woxsen University's Sustainability Week

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Rahul Gandhi's disqualification from LS ...
Greater Noida: Stray dog attacks girl, d...
Andhra urges Centre to extend SC status ...
Gujarat Police carries out inspection in...
Leopard's skeleton found in Gurugram...
Youth's body found hanging from tree in ...
More...    
 
 Top Stories
J-K: Two Lashkar terrorists arreste... 
J-K: Indian Army, Police foil infil... 
"Will take it seriously, discuss th... 
US working to assist Americans who ... 
165 injured in Iran's 5.6-magnitude... 
Rifle stolen from police station in... 
Bommai announces hike in reservatio... 
14 killed by flash floods in Somali...